CONTINUE TO SITE ➞

Don't miss tomorrow's biopharma industry news

Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.

Daily Dive M-F

Commercialization Weekly Every Wednesday

Gene Therapy Weekly Every Thursday

Emerging Biotech Weekly Every Tuesday

By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Deep Dive
Library
Events
Press Releases

Pharma
Biotech
FDA
Clinical Trials
Deals
Drug Pricing
Gene Therapy

What We're Reading: Page 34

Industry reads hand-picked by our editors

Sep 26, 2024

Endpoints News
J&J folds cardiovascular and metabolic drug unit
Financial Times
How tackling TB could help win the war on superbugs
Nature News
Why do obesity drugs seem to treat so many other ailments?

Sep 25, 2024

The Wall Street Journal
Roche Narrows Pharma Pipeline Amid Push Into Obesity Market
Axios
AI’s latest trick: repurposing old drugs for rare disease
Nature
Why do obesity drugs seem to treat so many other ailments?
Reuters
US FDA approves IntraBio’s drug for rare genetic disease

Sep 24, 2024

Bloomberg
$50 Billion in Sales Make Ozempic and Wegovy Prices Tougher to Justify
The New York Times
Anti-Aging Enthusiasts Are Taking a Pill to Extend Their Lives. Will It Work?
Science
Mpox may trigger large outbreak in one of Africa’s largest cities

Sep 23, 2024

Axios
Johnson & Johnson tries bankruptcy a third time for talc liabilities
The Financial Times
Vaccine alliance battles for funds as donors face financial pressures
STAT
A mysterious anti ‘Big Pharma’ bus is barnstorming swing states

Sep 20, 2024

Nature
Do AI models produce more original ideas than researchers?
Bloomberg
China Cracks Down on Illegal Copies of Novo’s Weight-Loss Drug
The Washington Post
Scientists again link covid pandemic origin to Wuhan market animals

Sep 19, 2024

Financial Times
Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’
NPR
Sickle cell gene therapies roll out slowly
C&EN
R&D for long COVID is collapsing

Sep 18, 2024

Bloomberg
Novo Says Ozempic ‘Very Likely’ Target for Next US Price Cut
FirstWord Pharma
Coherus’ Udenyca faces short-term supply squeeze
Endpoints News
After I was diagnosed with Merkel cell carcinoma, I discovered how a band of physician-scientists triggered a revolution

Previous Next

Get the free newsletter

Subscribe to BioPharma Dive for top news, trends & analysis

Email:

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

A valid email address is required. Please select at least one newsletter.

Library resources

Playbook
Navigating New Opportunities in China's Pharmaceutical Boom Custom content for Evaluate
Trendline
Inside the world of cell therapies Supported by 10x Genomics
Infographic
Accelerate clinical trials: Break silos, reduce delays Custom content for WCG

View all

Company Announcements

View all | Post a press release

Events

View all | Promote an event

Industry Intel

4 major trends shaping today’s oncology market Webinar - on demand • Provided by Advisory Board
Built for the Storm: Why Prepared Systems Win in Pharma Webinar - on demand • Provided by Phase2
Trends and Innovations in Life Science Qualitative Research Webinar - on demand • Provided by Konovo

Explore

About
Editorial Team
Contact Us
Newsletter
Purchase Licensing Rights
Press Releases
What We're Reading

Reach our audience

Advertising
Post a press release
Promote an event

Related Publications

Healthcare Dive
MedTech Dive

Industry Dive is an Informa TechTarget business.

This website is owned and operated by Informa TechTarget, part of a global network that informs, influences and connects the world's technology buyers and sellers. All copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. TechTarget, Inc.'s registered office is 275 Grove St. Newton, MA 02466.

Home
- Pharma
- Biotech
- FDA
- Clinical Trials
- Deals
- Drug Pricing
- Gene Therapy
Deep Dive
Library
Events
Press Releases

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Email:

Select Newsletter: Daily Dive M-F
Select Newsletter: Commercialization Weekly Every Wednesday
Select Newsletter: Gene Therapy Weekly Every Thursday
Select Newsletter: Emerging Biotech Weekly Every Tuesday
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

A valid email address is required. Please select at least one newsletter.